(4E,7E,10E,13E,16E,19E)-Docosa-4,7,10,13,16,19-hexaenoic acid | 391921-09-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (4E,7E,10E,13E,16E,19E)-Docosa-4,7,10,13,16,19-hexaenoic acid
• 英文别名: Docosahexaenoic acid；trans-docosahexaenoic acid；docosahexanoic acid；trans-DHA；4,7,10,13,16,19-Docosahexaenoic acid
• CAS: 391921-09-8
• 化学式: C₂₂H₃₂O₂
• 分子量: 328.495
• InChiKey: MBMBGCFOFBJSGT-SFGLVEFQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4E,7E,10E,13E,16E,19E)-Docosa-4,7,10,13,16,19-hexaenoic acid 生成 methyl 3-[3-[(2E,5E,8E,11E,14E)-heptadeca-2,5,8,11,14-pentaenyl]oxiran-2-yl]propanoate
  参考文献：
  名称：

  SHEVCHENKO, V. P.;NAGAEV, I. YU.;MYASOEDOV, N. F.;KUKLEV, D. V.;IMBO, A. +, SINTEZ I ISSLED. PROSTAGLANDINOV, MINSK,(1989) S. 83

  摘要：

  DOI：
• 作为试剂：
  描述：

  N-(2-aminoethyl)-2-hydroxybenzamide hydrochloride 、 (4E,7E,10E,13E,16E,19E)-Docosa-4,7,10,13,16,19-hexaenoic acid 在 (4E,7E,10E,13E,16E,19E)-Docosa-4,7,10,13,16,19-hexaenoic acid 作用下， 生成 艾得奈生
  参考文献：
  名称：

  J. Med. Chem. 2016, 59, 1217-1231

  摘要：

  DOI：

文献信息

• Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20060104998A1

  公开（公告）日：2006-05-18

  The present invention is directed to substituted 4H-chromenes and analogs thereof, represented by the Formula (I): wherein R 1 , R 3 -R 5 , A, D, Y and Z are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及被代替的4H-香豆素及其类似物，由式（I）表示：其中R1，R3-R5，A，D，Y和Z在此处定义。本发明还涉及发现具有式（I）的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在发生细胞不受控制生长和异常细胞扩散的各种临床状况中的细胞死亡。
• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：US20160129122A1

  公开（公告）日：2016-05-12

  The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate.

  这项发明涉及脂肪酸抗病毒共轭物；包含有效量脂肪酸抗病毒共轭物的组合物；以及治疗或预防病毒感染的方法，包括给予有效量脂肪酸抗病毒共轭物。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS
  申请人：Dietz Ulrich

  公开号：US20140099354A1

  公开（公告）日：2014-04-10

  The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses.

  本发明涉及一种含硝基羧酸（s）的磷脂，用于涂覆医疗器械，如支架、导管球囊、伤口垫或外科缝合材料，以及用于生物钝化组合物，如漱口液、防水溶液、涂层溶液、冷冻保护溶液、冷藏介质、冻干保护溶液、造影介质溶液、含有这些化合物的保存和再灌注溶液，以及制备这些溶液和涂覆医疗器械以及它们的用途。